1006 ET - Centene logged better 3Q earnings than analysts had expected despite seeing higher-than-expected acuity--a measure of illness severity--in its Medicaid patient population after redeterminations, Mizuho analyst Ann Hynes says in a research note. The company's strong position in the individual marketplace continues to offset these Medicaid pressures, the analyst says. The managed healthcare provider delivered a solid quarter in contrast to its peers' results, which seem to have spooked investors, Hynes says. Centene's stock fell 23% between Sept. 1 and this morning's earnings release. Cost trends will be a main focus of management's call with analysts, Hynes says. Shares rise 11% to $68.53. (dean.seal@wsj.com)
(END) Dow Jones Newswires
October 25, 2024 10:06 ET (14:06 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。